2020
Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer
Malani R, Fleisher M, Kumthekar P, Lin X, Omuro A, Groves MD, Lin NU, Melisko M, Lassman AB, Jeyapalan S, Seidman A, Skakodub A, Boire A, DeAngelis LM, Rosenblum M, Raizer J, Pentsova E. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. Journal Of Neuro-Oncology 2020, 148: 599-606. PMID: 32506369, PMCID: PMC7438284, DOI: 10.1007/s11060-020-03555-z.Peer-Reviewed Original ResearchConceptsLeptomeningeal metastasesCSF cytologyCSF CTCsCTC enumerationCerebrospinal fluidIT trastuzumabPhase I/II dose escalation trialCentral nervous system compartmentTumor cellsHER2/neu positivityHER2/neu expressionDose-escalation trialHER2-positive cancersIntrathecal trastuzumabEscalation trialRadiographic responseTumor burdenPositive cancersNeu expressionNeu positivityConclusionOur studyPatientsDay 1Epithelial cancersCancer
2012
Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis
Pentsova E, Rosenblum M, Holodny A, Palomba ML, Omuro A. Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis. Leukemia & Lymphoma 2012, 53: 1620-1622. PMID: 22242822, DOI: 10.3109/10428194.2012.656632.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic AgentsAutopsyBrainBrain InjuriesChlorambucilCytarabineDisease ProgressionFatal OutcomeHumansInjections, SpinalLeukemia, Lymphocytic, Chronic, B-CellMagnetic Resonance ImagingMaleMethotrexateNervous System DiseasesPositron-Emission TomographyRecurrenceWaldenstrom Macroglobulinemia
2011
Prophylactic intrathecal chemotherapy in primary CNS lymphoma
Sierra del Rio M, Ricard D, Houillier C, Navarro S, Gonzalez-Aguilar A, Idbaih A, Kaloshi G, Elhallani S, Omuro A, Choquet S, Soussain C, Hoang-Xuan K. Prophylactic intrathecal chemotherapy in primary CNS lymphoma. Journal Of Neuro-Oncology 2011, 106: 143-146. PMID: 21739169, DOI: 10.1007/s11060-011-0649-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntimetabolites, AntineoplasticAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCohort StudiesDisease-Free SurvivalFemaleFollow-Up StudiesHumansInjections, SpinalKarnofsky Performance StatusLomustineLymphomaMaleMethotrexateMethylprednisoloneMiddle AgedNeoplasm Recurrence, LocalNeuroprotective AgentsProcarbazineRetrospective StudiesYoung AdultConceptsPrimary central nervous system lymphomaCentral nervous system lymphomaNervous system lymphomaProphylactic intrathecal chemotherapyIntrathecal chemotherapySystem lymphomaIntrathecal prophylaxisHigh-dose intravenous methotrexateRetrospective single-center studyObjective response ratePatterns of relapsePrimary CNS lymphomaProgression-free survivalSingle-center studyHigh intravenous dosesIntrathecal chemoprophylaxisIntravenous methotrexateProphylaxis withdrawalChemotherapy regimenCNS lymphomaSystemic chemotherapyKarnofsky indexOverall survivalIntravenous dosesMedian age
2005
Chemoradiotherapy for primary CNS lymphoma
Omuro AM, DeAngelis LM, Yahalom J, Abrey LE. Chemoradiotherapy for primary CNS lymphoma. Neurology 2005, 64: 69-74. PMID: 15642906, DOI: 10.1212/01.wnl.0000148641.98241.5e.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaLong-term outcomesComplete responsePartial responseCNS lymphomaMedian Karnofsky Performance Scale scoreMedian disease-free survivalProspective phase II trialKarnofsky Performance Scale scoreIncidence of neurotoxicityWhole brain radiotherapyMedian overall survivalDisease-free survivalPhase II trialYear of diagnosisPerformance Scale scoreChemotherapy regimenChemotherapy regimensFifteen patientsFirst relapseII trialMinor complicationsOverall survivalModality treatmentDisease progression